Evidence map›Paper›PMID 22292809›Full record

ReviewCurrent drug metabolism2012

Dynamic factors controlling targeting nanocarriers to vascular endothelium.

Vladimir R Muzykantov, Ravi Radhakrishnan, David M Eckmann

Open access · greenAbstract readReview
In one paragraph

Review in Current drug metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 31 citations in OpenAlex.

  1. Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  17. Review
  18. Article
  19. Nanoparticles in Medicine: Selected Observations and Experimental Caveats.Proceedings of SPIE--the International Society for Optical Engineering · 2013
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vladimir R MuzykantovUniversity of Pennsylvania, Philadelphia, PA 19104-4215, USA. eckmanndm@uphs.upenn.edu
Ravi Radhakrishnan
David M Eckmann
University of Pennsylvania · US

Funding

Targeted Microcarrier Design and OptimizationR01EB006818 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI ECKMANN, DAVID M · 2008 to 2016
$3.3M
Targeting Carriers with Controlled Geometry to EndotheliumR01HL087036 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2008 to 2012
$2.0M
NHLBI NIH HHS R01 HL087036NIBIB NIH HHS R01 EB006818
6 · The paper itself

Abstract

Endothelium lining the luminal surface of blood vessels is the key target and barrier for vascular drug delivery. Nanocarriers coated with antibodies or affinity peptides that bind specifically to endothelial surface determinants provide targeted delivery of therapeutic cargoes to these cells. Endothelial targeting consists of several phases including circulation in the bloodstream, anchoring on the endothelial surface and, in some cases, intracellular uptake and trafficking of the internalized materials. Dynamic parameters of the vasculature including the blood hydrodynamics as well as surface density, accessibility, membrane mobility and clustering of target determinants modulate these phases of the targeting, especially anchoring to endothelium. Further, such controlled parameters of design of drug nanocarriers such as affinity, surface density and epitope specificity of targeting antibodies, carrier size and shape also modulate endothelial targeting and resultant sub-cellular addressing. This article reviews experimental and computational approaches for analysis of factors modulating targeting nanocarriers to the endothelial cells.

Indexed as

AnimalsDrug CarriersDrug Delivery SystemsEndothelium, VascularHumansNanoparticlesDrug Carriers

Identifiers

PMID22292809
PMCPMC3294139
OpenAlexW2064788028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.